HGH Fragment 176-191 is an experimental, unapproved peptide. The amounts below are commonly cited and anecdotal, not medically established, and human evidence is limited. Responsible use, if any, is start-low and supervised. Any real decision belongs with a qualified clinician.
Overview
HGH Fragment 176-191 is a C-terminal piece of the growth hormone molecule studied mainly for fat metabolism. Because it is unapproved and lacks robust human trials, there is no validated dosing standard — only patterns repeated in the peptide community.
Common dosing pattern
The pattern most often cited (anecdotal, not established) is:
- Roughly 250-500 mcg per injection, given one to two times per day subcutaneously.
- When taken more than once daily, doses are commonly split (for example, morning and evening).
- People commonly start at the lower end and adjust by tolerance rather than beginning high.
- Some discussion favors a fasted state around dosing, though evidence for any particular timing is thin.
These figures are widely repeated but are not derived from approved human dosing.
How it is administered
The fragment is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with a sterile diluent before subcutaneous injection.
- The delivered amount depends on reconstitution (how much diluent is added) and on reading syringe units as volume — a common source of error.
- Native fragments can degrade quickly, which is one reason a stabilized analog (AOD-9604) was engineered.
Why oversight matters
Because this fragment is unapproved and inadequately studied in humans, there is no verified label, and raw research powders vary in quality and sterility. A clinician can weigh the limited evidence against an individual's health, medications, and goals — judgment a reference figure cannot provide.